Identification
NameVortioxetine
Accession NumberDB09068  (DB05700)
TypeSmall Molecule
GroupsApproved
Description

Vortioxetine is an atypical antipsychotic and antidepressant indicated for the treatment of major depressive disorder (MDD). It is classified as a serotonin modulator and simulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and an antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors. SMSs were developed because there are many different subtypes of serotonin receptors, however, not all of these receptors appear to be involved in the antidepressant effects of SRIs. Some serotonin receptors seem to play a relatively neutral or insignificant role in the regulation of mood, but others, such as 5-HT1A autoreceptors and 5-HT7 receptors, appear to play an oppositional role in the efficacy of SRIs in treating depression.

Structure
Thumb
Synonyms
4-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazin-1-ium
vortioxetine cation
External IDs Lu AA21004 / Lu-AA21004 / LuAA21004
Product Ingredients
IngredientUNIICASInChI KeyDetails
vortioxetine hydrobromideTKS641KOAY 960203-27-4VNGRUFUIHGGOOM-UHFFFAOYSA-NDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BrintellixTablet, film coated5 mg/1OralTakeda2013-10-02Not applicableUs
BrintellixTablet, film coated10 mg/1OralAvera Mc Kennan Hospital2015-06-05Not applicableUs
BrintellixTablet, film coated20 mg/1OralTakeda2013-10-02Not applicableUs
BrintellixTablet, film coated10 mg/1OralTakeda2013-10-02Not applicableUs64764 0560 30 nlmimage10 5a3a2d71
BrintellixTablet, film coated15 mg/1OralTakeda2013-10-02Not applicableUs
TrintellixTablet, film coated10 mg/1OralAvera Mc Kennan Hospital2016-06-20Not applicableUs
TrintellixTablet, film coated20 mg/1OralTakeda2013-10-02Not applicableUs
TrintellixTablet20 mgOralLundbeck Inc.2014-10-28Not applicableCanada
TrintellixTablet, film coated5 mg/1OralTakeda2013-10-02Not applicableUs
TrintellixTablet5 mgOralLundbeck Inc.2014-10-28Not applicableCanada
TrintellixTablet15 mgOralLundbeck Inc.Not applicableNot applicableCanada
TrintellixTablet, film coated10 mg/1OralTakeda2013-10-02Not applicableUs
TrintellixTablet10 mgOralLundbeck Inc.2014-10-28Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII3O2K1S3WQV
CAS number508233-74-7
WeightAverage: 299.46
Monoisotopic: 299.157646343
Chemical FormulaC18H23N2S
InChI KeyYQNWZWMKLDQSAC-UHFFFAOYSA-O
InChI
InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3/p+1
IUPAC Name
4-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazin-1-ium
SMILES
CC1=CC(C)=C(SC2=CC=CC=C2N2CC[NH2+]CC2)C=C1
Pharmacology
Indication

Vortioxetine is indicated for the treatment of major depressive disorder (MDD).

Structured Indications
Pharmacodynamics

Vortioxetine binds with high affinity to the human serotonin transporter (Ki=1.6 nM), but not to the norepinephrine (Ki=113 nM) or dopamine (Ki>1000 nM) transporters. Vortioxetine potently and selectively inhibits reuptake of serotonin by inhibition of the serotonin transporter (IC50=5.4 nM). Specifically, vortioxetine binds to 5­HT3 (Ki=3.7 nM), 5­HT1A (Ki=15 nM), 5­HT7 (Ki=19 nM), 5­HT1D (Ki=54 nM), and 5­HT1B (Ki=33 nM), receptors and is a 5­HT3, 5­HT1D, and 5­HT7 receptor antagonist, 5­HT1B receptor partial agonist, and 5­HT1A receptor agonist.

Mechanism of action

Vortioxetine is classified as a serotonin modulator and simulator (SMS) as it has a multimodal mechanism of action towards the serotonin neurotransmitter system whereby it simultaneously modulates one or more serotonin receptors and inhibits the reuptake of serotonin. More specifically, vortioxetine acts via the following biological mechanisms: as a serotonin reuptake inhibitor (SRI) through inhibition of the serotonin transporter, while also acting as a partial agonist of the 5-HT1B receptor, an agonist of 5-HT1A, and antagonist of the 5-HT3, 5-HT1D, and 5-HT7 receptors.

TargetKindPharmacological actionActionsOrganismUniProt ID
Sodium-dependent serotonin transporterProteinyes
inhibitor
HumanP31645 details
5-hydroxytryptamine receptor 3AProteinyes
antagonist
HumanP46098 details
5-hydroxytryptamine receptor 7Proteinyes
antagonist
HumanP34969 details
5-hydroxytryptamine receptor 1BProteinyes
partial agonist
HumanP28222 details
5-hydroxytryptamine receptor 1AProteinyes
agonist
HumanP08908 details
Beta-1 adrenergic receptorProteinunknown
ligand
HumanP08588 details
solute carrier family 6 member 2Proteinunknown
blocker
Humannot applicabledetails
Related Articles
Absorption

The maximal plasma vortioxetine concentration (Cmax) after dosing is reached within 7 to 11 hours postdose. Absolute bioavailability is 75%. No effect of food on the pharmacokinetics was observed.

Volume of distribution

The apparent volume of distribution of vortioxetine is approximately 2600 L, indicating extensive extravascular distribution.

Protein binding

The plasma protein binding of vortioxetine in humans is 98%, independent of plasma concentrations. No apparent difference in the plasma protein binding between healthy subjects and subjects with hepatic (mild, moderate) or renal (mild, moderate, severe, ESRD) impairment is observed.

Metabolism

Vortioxetine is extensively metabolized primarily through oxidation via cytochrome P450 isozymes CYP2D6, CYP3A4/5, CYP2C19, CYP2C9, CYP2A6, CYP2C8 and CYP2B6 and subsequent glucuronic acid conjugation. CYP2D6 is the primary enzyme catalyzing the metabolism of vortioxetine to its major, pharmacologically inactive, carboxylic acid metabolite, and poor metabolizers of CYP2D6 have approximately twice the vortioxetine plasma concentration of extensive metabolizers.

SubstrateEnzymesProduct
Vortioxetine
Vortioxetine Metabolite 1Details
Vortioxetine Metabolite 1
M0Details
Vortioxetine
M8Details
Vortioxetine
Vortioxetine Metabolite 2Details
Route of elimination

Following a single oral dose of [14C]­labeled vortioxetine, approximately 59% and 26% of the administered radioactivity was recovered in the urine and feces, respectively as metabolites. Negligible amounts of unchanged vortioxetine were excreted in the urine up to 48 hours.

Half life

Mean terminal half­life is approximately 66 hours

ClearanceNot Available
Toxicity

The most commonly reported adverse effects during clinical trials were nausea, diarrhea, and dry mouth. The FDA label includes a blackbox warning for the following risks and complications: serotonin syndrome, especially when combined with other serotonergic agents; increased risk of abnormal bleeding, especially when combined with NSAIDs, aspirin, or other drugs that affect coagulation; activation of mania/hypomania; hyponatremia; and suicidal thoughts and behaviour in children, adolescents, and young adults.

Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC allele Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC allele Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delT Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>C Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>T Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>C Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>A Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>A Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACT Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insG Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACT Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2 Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGT Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>T Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower maximum dose. Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer, lower maximum dose. Details
Interactions
Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Vortioxetine.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe metabolism of Vortioxetine can be decreased when combined with 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AbirateroneThe serum concentration of Vortioxetine can be increased when it is combined with Abiraterone.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Vortioxetine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Vortioxetine.Approved
AcetophenazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Acetophenazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Vortioxetine.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Vortioxetine.Approved, Investigational
AlfaxaloneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Vortioxetine.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when Alimemazine is combined with Vortioxetine.Approved, Vet Approved
AllopregnanoloneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Sage 547.Investigational
AlmotriptanThe risk or severity of adverse effects can be increased when Almotriptan is combined with Vortioxetine.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Vortioxetine.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Vortioxetine.Approved, Illicit, Investigational
AmiodaroneThe serum concentration of Vortioxetine can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Vortioxetine.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Vortioxetine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Vortioxetine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Vortioxetine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Vortioxetine.Experimental
AprepitantThe serum concentration of Vortioxetine can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Vortioxetine.Approved, Investigational
ArmodafinilThe metabolism of Vortioxetine can be decreased when combined with Armodafinil.Approved, Investigational
ArtemetherThe metabolism of Vortioxetine can be decreased when combined with Artemether.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Vortioxetine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Vortioxetine.Approved
AtazanavirThe metabolism of Vortioxetine can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Vortioxetine can be decreased when combined with Atomoxetine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Azaperone.Vet Approved
AzelastineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Vortioxetine.Illicit
BenmoxinThe metabolism of Vortioxetine can be decreased when combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Vortioxetine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Vortioxetine.Approved
BetaxololThe metabolism of Vortioxetine can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Vortioxetine can be decreased when it is combined with Bexarotene.Approved, Investigational
BifeprunoxThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Bifeprunox.Investigational
BL-1020The risk or severity of adverse effects can be increased when BL-1020 is combined with Vortioxetine.Investigational
BoceprevirThe metabolism of Vortioxetine can be decreased when combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Vortioxetine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Vortioxetine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Vortioxetine.Approved, Illicit
BromocriptineBromocriptine may increase the vasoconstricting activities of Vortioxetine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Vortioxetine.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Vortioxetine.Approved, Investigational
BuprenorphineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Vortioxetine.Approved
BuspironeBuspirone may increase the serotonergic activities of Vortioxetine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Vortioxetine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Vortioxetine.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Vortioxetine.Approved, Illicit, Vet Approved
CabergolineCabergoline may increase the vasoconstricting activities of Vortioxetine.Approved
CapecitabineThe metabolism of Vortioxetine can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe serum concentration of Vortioxetine can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Vortioxetine.Illicit, Vet Approved
CariprazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cariprazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Carisoprodol.Approved
CaroxazoneThe metabolism of Vortioxetine can be decreased when combined with Caroxazone.Withdrawn
CelecoxibThe metabolism of Vortioxetine can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Vortioxetine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Vortioxetine.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Vortioxetine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Vortioxetine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Vortioxetine.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Vortioxetine.Approved
ChloroquineThe metabolism of Vortioxetine can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Chlorphenamine.Approved
ChlorpromazineThe metabolism of Vortioxetine can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Vortioxetine.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Chlorzoxazone.Approved
CholecalciferolThe metabolism of Vortioxetine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Vortioxetine can be decreased when combined with Cimetidine.Approved
CinacalcetThe serum concentration of Vortioxetine can be increased when it is combined with Cinacalcet.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Vortioxetine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Citalopram is combined with Vortioxetine.Approved
ClarithromycinThe metabolism of Vortioxetine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Vortioxetine can be decreased when combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clidinium.Approved
ClobazamThe metabolism of Vortioxetine can be decreased when combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Vortioxetine.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Vortioxetine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Clonidine.Approved
ClopidogrelThe metabolism of Vortioxetine can be decreased when combined with Clopidogrel.Approved, Nutraceutical
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Vortioxetine.Approved, Illicit
ClotrimazoleThe metabolism of Vortioxetine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Vortioxetine can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Vortioxetine can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Vortioxetine can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Vortioxetine.Approved, Illicit
ConivaptanThe serum concentration of Vortioxetine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Vortioxetine can be decreased when combined with Crizotinib.Approved
CyamemazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Vortioxetine.Approved
CyclosporineThe metabolism of Vortioxetine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Vortioxetine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Vortioxetine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Dapoxetine is combined with Vortioxetine.Investigational
DarifenacinThe metabolism of Vortioxetine can be decreased when combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Vortioxetine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Vortioxetine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Vortioxetine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Vortioxetine can be increased when it is combined with Delavirdine.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Vortioxetine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Vortioxetine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Vortioxetine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Vortioxetine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Vortioxetine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Vortioxetine.Approved, Vet Approved
DextromethorphanThe risk or severity of adverse effects can be increased when Dextromethorphan is combined with Vortioxetine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Vortioxetine.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Vortioxetine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Vortioxetine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Vortioxetine.Approved, Illicit, Vet Approved
DifenoxinThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Vortioxetine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the vasoconstricting activities of Vortioxetine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Vortioxetine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Vortioxetine.Experimental, Illicit
DiltiazemThe metabolism of Vortioxetine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Dimenhydrinate.Approved
DiphenhydramineThe metabolism of Vortioxetine can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Vortioxetine.Approved, Illicit
DolasetronDolasetron may increase the serotonergic activities of Vortioxetine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Vortioxetine.Approved
DoxorubicinThe metabolism of Vortioxetine can be decreased when combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Vortioxetine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Vortioxetine.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Illicit
DronedaroneThe metabolism of Vortioxetine can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Vortioxetine.Experimental, Illicit
DroxidopaVortioxetine may increase the hypertensive activities of Droxidopa.Approved, Investigational
DuloxetineThe risk or severity of adverse effects can be increased when Duloxetine is combined with Vortioxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Vortioxetine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Vortioxetine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Vortioxetine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe risk or severity of adverse effects can be increased when Eletriptan is combined with Vortioxetine.Approved, Investigational
EliglustatThe metabolism of Vortioxetine can be decreased when combined with Eliglustat.Approved
EltanoloneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pregnanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Vortioxetine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Vortioxetine can be decreased when it is combined with Enzalutamide.Approved
Ergoloid mesylateErgoloid mesylate may increase the vasoconstricting activities of Vortioxetine.Approved
ErgonovineErgonovine may increase the vasoconstricting activities of Vortioxetine.Approved
ErgotamineErgotamine may increase the vasoconstricting activities of Vortioxetine.Approved
ErythromycinThe metabolism of Vortioxetine can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Escitalopram is combined with Vortioxetine.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Vortioxetine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Vortioxetine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Vortioxetine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Vortioxetine.Approved
EthanolVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Vortioxetine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Vortioxetine.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Vortioxetine.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Vortioxetine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Vortioxetine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Vortioxetine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Vortioxetine.Approved
EtoperidoneEtoperidone may increase the serotonergic activities of Vortioxetine.Approved
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Vortioxetine.Illicit, Vet Approved
EtravirineThe serum concentration of Vortioxetine can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Felbamate.Approved
FelodipineThe metabolism of Vortioxetine can be decreased when combined with Felodipine.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Vortioxetine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Vortioxetine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Flibanserin.Approved
FloxuridineThe metabolism of Vortioxetine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Vortioxetine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Vortioxetine.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Vortioxetine.Approved, Illicit
FluorouracilThe metabolism of Vortioxetine can be decreased when combined with Fluorouracil.Approved
FluoxetineThe serum concentration of Vortioxetine can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Vortioxetine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Vortioxetine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Vortioxetine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Vortioxetine.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Vortioxetine can be decreased when combined with Fluvastatin.Approved
FluvoxamineThe metabolism of Vortioxetine can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Vortioxetine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Vortioxetine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Vortioxetine can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Vortioxetine.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Vortioxetine.Approved, Investigational
FurazolidoneThe metabolism of Vortioxetine can be decreased when combined with Furazolidone.Approved, Vet Approved
Fusidic AcidThe serum concentration of Vortioxetine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Vortioxetine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Vortioxetine is combined with gabapentin enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Vortioxetine.Approved, Illicit
GemfibrozilThe metabolism of Vortioxetine can be decreased when combined with Gemfibrozil.Approved
GepironeThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Vortioxetine.Approved, Illicit
GranisetronGranisetron may increase the serotonergic activities of Vortioxetine.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Vortioxetine.Approved, Illicit, Withdrawn
HaloperidolThe metabolism of Vortioxetine can be decreased when combined with Haloperidol.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Vortioxetine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Vortioxetine.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Vortioxetine.Approved
HydracarbazineThe metabolism of Vortioxetine can be decreased when combined with Hydracarbazine.Experimental
HydrocodoneVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Vortioxetine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
IdelalisibThe serum concentration of Vortioxetine can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Iloperidone.Approved
ImatinibThe metabolism of Vortioxetine can be decreased when combined with Imatinib.Approved
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Vortioxetine.Approved
IndalpineIndalpine may increase the serotonergic activities of Vortioxetine.Investigational, Withdrawn
IndinavirThe metabolism of Vortioxetine can be decreased when combined with Indinavir.Approved
IproclozideThe metabolism of Vortioxetine can be decreased when combined with Iproclozide.Withdrawn
IproniazidThe metabolism of Vortioxetine can be decreased when combined with Iproniazid.Withdrawn
IrbesartanThe metabolism of Vortioxetine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Vortioxetine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe metabolism of Vortioxetine can be decreased when combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Vortioxetine.Approved, Vet Approved
IsoniazidThe metabolism of Vortioxetine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Vortioxetine can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Vortioxetine can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Vortioxetine can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Vortioxetine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Vortioxetine.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Vortioxetine.Approved
KetoconazoleThe metabolism of Vortioxetine can be decreased when combined with Ketoconazole.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Lamotrigine.Approved, Investigational
LapatinibThe metabolism of Vortioxetine can be decreased when combined with Lapatinib.Approved, Investigational
LeflunomideThe metabolism of Vortioxetine can be decreased when combined with Leflunomide.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Vortioxetine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Vortioxetine.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Levomilnacipran is combined with Vortioxetine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Vortioxetine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Vortioxetine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Vortioxetine.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Vortioxetine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Lofentanil.Illicit
LopinavirThe serum concentration of Vortioxetine can be increased when it is combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Vortioxetine.Approved
LorcaserinThe risk or severity of adverse effects can be increased when Lorcaserin is combined with Vortioxetine.Approved
LosartanThe metabolism of Vortioxetine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Vortioxetine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Vortioxetine.Approved
LuliconazoleThe serum concentration of Vortioxetine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Vortioxetine can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe metabolism of Vortioxetine can be decreased when combined with Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Vortioxetine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Vortioxetine.Approved
MebanazineThe metabolism of Vortioxetine can be decreased when combined with Mebanazine.Withdrawn
MeclizineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Vortioxetine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Vortioxetine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Vortioxetine.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Vortioxetine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Vortioxetine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Vortioxetine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Vortioxetine.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Vortioxetine.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Vortioxetine.Approved
MethotrimeprazineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Vortioxetine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Vortioxetine.Experimental
Methylene blueThe metabolism of Vortioxetine can be decreased when combined with Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Vortioxetine.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Metoclopramide.Approved, Investigational
MetoprololThe metabolism of Vortioxetine can be decreased when combined with Metoprolol.Approved, Investigational
MetyrosineVortioxetine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Vortioxetine.Approved, Illicit
MifepristoneThe serum concentration of Vortioxetine can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Milnacipran is combined with Vortioxetine.Approved
MinaprineThe metabolism of Vortioxetine can be decreased when combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Investigational
MirabegronThe metabolism of Vortioxetine can be decreased when combined with Mirabegron.Approved
MirtazapineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Vortioxetine can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Vortioxetine can be decreased when combined with Moclobemide.Approved
ModafinilThe serum concentration of Vortioxetine can be decreased when it is combined with Modafinil.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Vortioxetine.Approved
MoricizineThe risk or severity of adverse effects can be increased when Moricizine is combined with Vortioxetine.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Vortioxetine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved, Investigational
NafcillinThe serum concentration of Vortioxetine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Vortioxetine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Vortioxetine.Approved, Investigational
NefazodoneThe metabolism of Vortioxetine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Vortioxetine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Vortioxetine can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Vortioxetine can be decreased when it is combined with Nevirapine.Approved
NialamideThe metabolism of Vortioxetine can be decreased when combined with Nialamide.Withdrawn
NicardipineThe metabolism of Vortioxetine can be decreased when combined with Nicardipine.Approved
NicotineThe metabolism of Vortioxetine can be decreased when combined with Nicotine.Approved
NilotinibThe metabolism of Vortioxetine can be decreased when combined with Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Vortioxetine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Vortioxetine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Vortioxetine.Approved
OctamoxinThe metabolism of Vortioxetine can be decreased when combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Vortioxetine.Approved, Investigational
OlaparibThe metabolism of Vortioxetine can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Vortioxetine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronOndansetron may increase the serotonergic activities of Vortioxetine.Approved
OpiumThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Opium.Approved, Illicit
OrphenadrineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Vortioxetine.Investigational
OsimertinibThe serum concentration of Vortioxetine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Vortioxetine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Vortioxetine.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Vortioxetine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Vortioxetine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Vortioxetine.Approved, Investigational, Vet Approved
PalbociclibThe serum concentration of Vortioxetine can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Vortioxetine.Approved
PalonosetronPalonosetron may increase the serotonergic activities of Vortioxetine.Approved, Investigational
PanobinostatThe serum concentration of Vortioxetine can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Vortioxetine can be decreased when combined with Pantoprazole.Approved
ParaldehydeVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineThe metabolism of Vortioxetine can be decreased when combined with Pargyline.Approved
ParoxetineThe serum concentration of Vortioxetine can be increased when it is combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Vortioxetine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Vortioxetine.Approved, Vet Approved
PentobarbitalThe serum concentration of Vortioxetine can be decreased when it is combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with Vortioxetine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Vortioxetine.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Vortioxetine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Vortioxetine.Approved
PhenelzineThe metabolism of Vortioxetine can be decreased when combined with Phenelzine.Approved
PheniprazineThe metabolism of Vortioxetine can be decreased when combined with Pheniprazine.Withdrawn
PhenobarbitalThe serum concentration of Vortioxetine can be decreased when it is combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Phenoxyethanol.Approved
PhenoxypropazineThe metabolism of Vortioxetine can be decreased when combined with Phenoxypropazine.Withdrawn
PhenytoinThe serum concentration of Vortioxetine can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Vortioxetine.Approved
PioglitazoneThe metabolism of Vortioxetine can be decreased when combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Piritramide.Investigational
PirlindoleThe metabolism of Vortioxetine can be decreased when combined with Pirlindole.Approved
PivhydrazineThe metabolism of Vortioxetine can be decreased when combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pomalidomide.Approved
PosaconazoleThe metabolism of Vortioxetine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleVortioxetine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Vortioxetine.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Vortioxetine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Vortioxetine.Approved
PrimidoneThe serum concentration of Vortioxetine can be decreased when it is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Vortioxetine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Vortioxetine.Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Vortioxetine.Approved, Vet Approved
PromazineThe metabolism of Vortioxetine can be decreased when combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Vortioxetine.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Vortioxetine.Approved, Vet Approved
PropericiazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Propericiazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when Propiopromazine is combined with Vortioxetine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Vortioxetine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Propoxycaine.Approved
ProthipendylThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Vortioxetine.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Vortioxetine.Investigational
PyrimethamineThe metabolism of Vortioxetine can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe serum concentration of Vortioxetine can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Vortioxetine.Approved
QuinidineThe serum concentration of Vortioxetine can be increased when it is combined with Quinidine.Approved
QuinineThe metabolism of Vortioxetine can be decreased when combined with Quinine.Approved
RabeprazoleThe metabolism of Vortioxetine can be decreased when combined with Rabeprazole.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ramelteon.Approved, Investigational
RanolazineThe metabolism of Vortioxetine can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineThe metabolism of Vortioxetine can be decreased when combined with Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Vortioxetine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Vortioxetine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Vortioxetine.Approved
RifabutinThe serum concentration of Vortioxetine can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Vortioxetine can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Vortioxetine can be decreased when it is combined with Rifapentine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Vortioxetine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ritanserin.Investigational
RitonavirThe serum concentration of Vortioxetine can be increased when it is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Vortioxetine.Approved
RolapitantThe metabolism of Vortioxetine can be decreased when combined with Rolapitant.Approved
RomifidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Romifidine.Vet Approved
RopiniroleVortioxetine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Vortioxetine.Approved
RosiglitazoneThe metabolism of Vortioxetine can be decreased when combined with Rosiglitazone.Approved, Investigational
RotigotineVortioxetine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Vortioxetine.Approved
SafrazineThe metabolism of Vortioxetine can be decreased when combined with Safrazine.Withdrawn
SaquinavirThe metabolism of Vortioxetine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Vortioxetine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Vortioxetine can be decreased when combined with Selegiline.Approved, Investigational, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Uc1010.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Vortioxetine.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Sertraline is combined with Vortioxetine.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Vortioxetine.Approved, Vet Approved
SildenafilThe metabolism of Vortioxetine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Vortioxetine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Vortioxetine can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
SorafenibThe metabolism of Vortioxetine can be decreased when combined with Sorafenib.Approved, Investigational
St. John's WortThe serum concentration of Vortioxetine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Vortioxetine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Vortioxetine.Approved, Investigational
SulfadiazineThe metabolism of Vortioxetine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Vortioxetine can be decreased when combined with Sulfamethoxazole.Approved
SulfisoxazoleThe metabolism of Vortioxetine can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Vortioxetine.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Vortioxetine.Approved, Investigational
SuvorexantVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Vortioxetine.Approved, Investigational
TamoxifenThe metabolism of Vortioxetine can be decreased when combined with Tamoxifen.Approved
TandospironeThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tasimelteon.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the serotonergic activities of Vortioxetine.Approved
TelaprevirThe metabolism of Vortioxetine can be decreased when combined with Telaprevir.Withdrawn
TelithromycinThe metabolism of Vortioxetine can be decreased when combined with Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Vortioxetine.Approved
TerbinafineThe serum concentration of Vortioxetine can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideThe metabolism of Vortioxetine can be decreased when combined with Teriflunomide.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Vortioxetine.Investigational
ThalidomideVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Vortioxetine.Approved, Vet Approved
ThiethylperazineThe risk or severity of adverse effects can be increased when Thiethylperazine is combined with Vortioxetine.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Vortioxetine.Approved, Vet Approved
ThioproperazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Thioproperazine.Approved
ThioridazineThe serum concentration of Vortioxetine can be increased when it is combined with Thioridazine.Withdrawn
ThiotepaThe metabolism of Vortioxetine can be decreased when combined with Thiotepa.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Vortioxetine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tiapride.Approved, Investigational
TicagrelorThe metabolism of Vortioxetine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Vortioxetine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tiletamine.Vet Approved
TipranavirThe serum concentration of Vortioxetine can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Vortioxetine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Vortioxetine can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Tolcapone.Approved, Withdrawn
ToloxatoneThe metabolism of Vortioxetine can be decreased when combined with Toloxatone.Approved
TopiramateThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Vortioxetine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe metabolism of Vortioxetine can be decreased when combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe metabolism of Vortioxetine can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Vortioxetine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Vortioxetine.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Vortioxetine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Vortioxetine.Approved, Vet Approved
TrimethoprimThe metabolism of Vortioxetine can be decreased when combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Vortioxetine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Triprolidine.Approved
TropisetronTropisetron may increase the serotonergic activities of Vortioxetine.Approved, Investigational
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Vortioxetine.Approved, Investigational
ValsartanThe metabolism of Vortioxetine can be decreased when combined with Valsartan.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Venlafaxine is combined with Vortioxetine.Approved
VerapamilThe metabolism of Vortioxetine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Vigabatrin.Approved
VilazodoneThe risk or severity of adverse effects can be increased when Vilazodone is combined with Vortioxetine.Approved
VoriconazoleThe metabolism of Vortioxetine can be decreased when combined with Voriconazole.Approved, Investigational
XylazineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Vortioxetine can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZafirlukastThe metabolism of Vortioxetine can be decreased when combined with Zafirlukast.Approved, Investigational
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Vortioxetine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Ziconotide.Approved
ZimelidineZimelidine may increase the serotonergic activities of Vortioxetine.Withdrawn
ZiprasidoneThe metabolism of Vortioxetine can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Vortioxetine.Approved, Investigational
ZolpidemVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Vortioxetine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Vortioxetine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Vortioxetine.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038 ]
  2. Stenkrona P, Halldin C, Lundberg J: 5-HTT and 5-HT(1A) receptor occupancy of the novel substance vortioxetine (Lu AA21004). A PET study in control subjects. Eur Neuropsychopharmacol. 2013 Oct;23(10):1190-8. doi: 10.1016/j.euroneuro.2013.01.002. Epub 2013 Feb 18. [PubMed:23428337 ]
  3. Mork A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M, Sanchez C: Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. Pharmacol Biochem Behav. 2013 Apr;105:41-50. doi: 10.1016/j.pbb.2013.01.019. Epub 2013 Feb 1. [PubMed:23380522 ]
  4. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396 ]
External Links
ATC CodesN06AX26 — Vortioxetine
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (749 KB)
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
0WithdrawnTreatmentCoronary Artery Disease / Major Depressive Disorder (MDD)1
1CompletedNot AvailableHealthy Volunteers1
1CompletedTreatmentDepressive State1
1CompletedTreatmentHealthy Men1
1CompletedTreatmentHealthy Volunteers1
1CompletedTreatmentPharmacokinetics1
1CompletedTreatmentSevere Hepatic Impairment1
2CompletedTreatmentAnxiety Disorder / Depressive Disorders1
2CompletedTreatmentAttention Deficit Hyperactivity Disorder (ADHD)1
2CompletedTreatmentMajor Depressive Disorder (MDD)4
2RecruitingTreatmentBinge Eating Disorder (BED)1
2, 3CompletedTreatmentMajor Depressive Disorder (MDD)1
2, 3Not Yet RecruitingOtherCognitive Change / Major Depressive Disorder (MDD)1
3CompletedTreatmentGeneralized Anxiety Disorder (GAD)5
3CompletedTreatmentMajor Depressive Disorder (MDD)22
3CompletedTreatmentTreatment Outcomes1
3Enrolling by InvitationTreatmentMajor Depressive Disorder (MDD)2
3RecruitingTreatmentMajor Depressive Disorder (MDD)3
3WithdrawnTreatmentMajor Depressive Disorder (MDD) / Tbi1
4Active Not RecruitingTreatmentHealthy Volunteers1
4Active Not RecruitingTreatmentMajor Depressive Disorder (MDD)1
4Active Not RecruitingTreatmentMajor Depressive Disorder (MDD) / Social Anxiety Disorder (SAD)1
4CompletedTreatmentDepressive State / Menopausal Hot Flushes / Menopause / Sleep / Vasomotor Disturbance1
4CompletedTreatmentPanic Disorders1
4Not Yet RecruitingDiagnosticMajor Depressive Disorder (MDD)1
4RecruitingBasic ScienceDepressive Disorders / Depressive State / Major Depressive Disorder (MDD) / Unipolar Depression1
4RecruitingOtherMajor Depressive Disorder (MDD)1
4RecruitingTreatmentAge-Related Cognitive Decline1
4RecruitingTreatmentMajor Depressive Disorder (MDD)3
4RecruitingTreatmentNegative Symptoms / Schizophrenic Disorders1
4RecruitingTreatmentPost-Traumatic Stress Disorder (PTSD)1
4WithdrawnTreatmentStage I, II or III Breast Cancer / Unipolar Major Depression1
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral5 mg/1
TabletOral10 mg
TabletOral15 mg
TabletOral20 mg
TabletOral5 mg
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US8476279 No2002-10-022022-10-02Us
US7144884 No2003-01-092023-01-09Us
US8969355 No2007-06-152027-06-15Us
US9227946 No2007-06-152027-06-15Us
US8722684 No2011-06-302031-06-30Us
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility7.0e-05 mg/mLALOGPS
logP1.62ALOGPS
logP4.76ChemAxon
logS-6.7ALOGPS
pKa (Strongest Basic)8.85ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area19.85 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity105.42 m3·mol-1ChemAxon
Polarizability35.28 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpiperazines. These are compounds containing a phenylpiperazine skeleton, which consists of a piperazine bound to a phenyl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentPhenylpiperazines
Alternative ParentsN-arylpiperazines / Diarylthioethers / m-Xylenes / Thiophenol ethers / Substituted anilines / Dialkylarylamines / Aminopyrazines / Quaternary ammonium salts / Sulfenyl compounds / Dialkylamines
SubstituentsN-arylpiperazine / Phenylpiperazine / Diarylthioether / M-xylene / Xylene / Substituted aniline / Dialkylarylamine / Thiophenol ether / Tertiary aliphatic/aromatic amine / Aminopyrazine
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorsammonium ion, organic cation (CHEBI:76017 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Uniprot Name:
Sodium-dependent serotonin transporter
Molecular Weight:
70324.165 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Voltage-gated potassium channel activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gated ion channel, which when activated causes fast, depolarizing responses in neurons. It is a cation-specific, but otherwise relatively nonselective, ion channel.
Gene Name:
HTR3A
Uniprot ID:
P46098
Uniprot Name:
5-hydroxytryptamine receptor 3A
Molecular Weight:
55279.835 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. The activity of this receptor is mediated by G proteins that stimulate adenylate cyclase.
Gene Name:
HTR7
Uniprot ID:
P34969
Uniprot Name:
5-hydroxytryptamine receptor 7
Molecular Weight:
53554.43 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
partial agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for ergot alkaloid derivatives, various anxiolytic and antidepressant drugs and other psychoactive substances, such as lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of ...
Gene Name:
HTR1B
Uniprot ID:
P28222
Uniprot Name:
5-hydroxytryptamine receptor 1B
Molecular Weight:
43567.535 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Beta-arrestin family members inhibit signaling via G pro...
Gene Name:
HTR1A
Uniprot ID:
P08908
Uniprot Name:
5-hydroxytryptamine receptor 1A
Molecular Weight:
46106.335 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
ligand
General Function:
Receptor signaling protein activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately equal affinity. Mediates Ras activation through G(s)-alpha- and cAMP-mediated signaling.
Gene Name:
ADRB1
Uniprot ID:
P08588
Uniprot Name:
Beta-1 adrenergic receptor
Molecular Weight:
51322.1 Da
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038 ]
7. solute carrier family 6 member 2
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
blocker
References
  1. Bang-Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mork A, Stensbol TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 2011 May 12;54(9):3206-21. doi: 10.1021/jm101459g. Epub 2011 Apr 12. [PubMed:21486038 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Uniprot Name:
Cytochrome P450 2D6
Molecular Weight:
55768.94 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396 ]
Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP3A5
Uniprot ID:
P20815
Uniprot Name:
Cytochrome P450 3A5
Molecular Weight:
57108.065 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Uniprot Name:
Cytochrome P450 2C19
Molecular Weight:
55930.545 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Uniprot Name:
Cytochrome P450 2C9
Molecular Weight:
55627.365 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Uniprot Name:
Cytochrome P450 2A6
Molecular Weight:
56501.005 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Uniprot Name:
Cytochrome P450 2C8
Molecular Weight:
55824.275 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396 ]
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Uniprot Name:
Cytochrome P450 2B6
Molecular Weight:
56277.81 Da
References
  1. Hvenegaard MG, Bang-Andersen B, Pedersen H, Jorgensen M, Puschl A, Dalgaard L: Identification of the cytochrome P450 and other enzymes involved in the in vitro oxidative metabolism of a novel antidepressant, Lu AA21004. Drug Metab Dispos. 2012 Jul;40(7):1357-65. doi: 10.1124/dmd.112.044610. Epub 2012 Apr 11. [PubMed:22496396 ]
Drug created on May 12, 2015 11:03 / Updated on September 01, 2017 12:01